1529 Treffer:
31.
A Phase 2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab Versus Placebo, in Combination With Pembrolizumab, Pemetrexed, and Carboplatin, in 1L Treatment of Participants With Metastatic NSCLC (GDFATHER-NS
NCT Heidelberg » Für Ärzte » Studien » Thorakale Tumoren » Bronchialkarzinom
Datum: 2026-05-09
32.
A Randomised, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With Secondary Resistance to Immune Checkpoint Inhibitor
NCT Heidelberg » Für Ärzte » Studien » Thorakale Tumoren » Bronchialkarzinom
Datum: 2026-05-09
33.
LUNAR-2: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab and Platinum-based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
NCT Heidelberg » Für Ärzte » Studien » Thorakale Tumoren » Bronchialkarzinom
Datum: 2026-05-09
34.
Maligne und rheumatische Erkrankungen - zwei Extreme des fehlgesteuerten Immunsystems Registerbasierte Erfassung und Erforschung der Zusammenhänge und Wechselbeziehungen zwischen malignen und rheumatischen Erkrankungen (RheuMal-, TRheuMa- und ParaRheuMa-
NCT Heidelberg » Für Ärzte » Studien » Thorakale Tumoren » Bronchialkarzinom
Datum: 2026-05-09
35.
Pulmonale Magnetresonanz-geführte online adaptive Radiotherapie von lokal-fortgeschrittenen Lungenkarzinomen Teil II (PUMA II)
NCT Heidelberg » Für Ärzte » Studien » Thorakale Tumoren » Bronchialkarzinom
Datum: 2026-05-09
36.
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Ex
NCT Heidelberg » Für Ärzte » Studien » Thorakale Tumoren » Bronchialkarzinom
Datum: 2026-05-09
37.
A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Partic
NCT Heidelberg » Für Ärzte » Studien » Thorakale Tumoren » Bronchialkarzinom
Datum: 2026-05-09
38.
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)
NCT Heidelberg » Für Ärzte » Studien » Thorakale Tumoren » Bronchialkarzinom
Datum: 2026-05-09
39.
Preoperative Amivantamab or Amivantamab and Carboplatin/pemetrexed Treatment in Patients with Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)
NCT Heidelberg » Für Ärzte » Studien » Thorakale Tumoren » Bronchialkarzinom
Datum: 2026-05-09
40.
A Multicenter Phase II Trial of Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in Homologous Recombination Deficiency (HRD) Positive Extensive Disease (ED) Small-ce
NCT Heidelberg » Für Ärzte » Studien » Thorakale Tumoren » Bronchialkarzinom
Datum: 2026-05-09